AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Active:	Yes
Cancer Type:	Multiple Myeloma	NCT ID:	NCT05850234
Trial Phases:	Phase I Phase II	Protocol IDs:	D8310C00001 (primary) NCI-2023-06014 GC012F-CD19/BCMA-001
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	AstraZeneca Pharmaceuticals LP
NCI Full Details:	http://clinicaltrials.gov/show/NCT05850234

Summary

This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual
CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.

Objectives

Phase 1b aims to evaluate the safety, tolerability, pharmacokinetic characteristics,
pharmacodynamic effect, and immunogenicity in subjects with relapsed/refractory multiple
myeloma and determine the recommended Phase 2 dose of AZD0120.

Phase II aims to evaluate the efficacy of AZD0120, and to further characterize the
safety, pharmacodynamic effects, immunogenicity, and changes in health-related quality of
life parameters in subjects with relapsed/refractory multiple myeloma.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.